Tozinameran is an mRNA vaccine for the prevention of COVID-19 caused by the SARS-CoV-2 virus. The Pfizer-BioNTech COVID-19 vaccine (also known as BNT162b2, Tozinameran, and Comirnaty), is one of four advanced mRNA-based vaccines developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.
- Mechanism
- Curator reviewed · 3 references
Comirnaty contains nucleoside modified mRNA (modRNA) encapsulated in lipid nanoparticles that deliver the modRNA into host cells. The lipid nanoparticle formulation facilitates the delivery of the RNA into human cells. Once inside these cells, the modRNA is translated by host machinery to produce a modified SARS-CoV-2 spike (S) protein antigen, which is subsequently recognized by the host immune system. Comirnaty has been shown to elicit both neutralizing antibody and cellular immune responses to the S protein, which helps protect against subsequent SARS-CoV-2 infection.
- Primary indication
- Comirnaty is fully approved by the FDA and Health Canada for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged five years and older.Curator reviewed · 8 structured indications
- First approval
- Canada, 2021 · United States, 2022 · European Union, 2021
- Also known as
- Pfizer-BioNTech COVID-19 Vaccine
- Code names
- BNT-162b2 · BNT162b2 SARS-CoV-2 Vaccine · RNA ingredient BNT-162B2
- Brand names
Resolves to
What you can answer from here — as of June 15, 2026
Which drugs share a target with Tozinameran, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account